The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.
https://www.pharmalive.com/wp-content/uploads/2023/09/AbbVie-office.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-14 09:09:192023-09-14 09:10:29AbbVie passes on license option for Harpoon’s TriTAC multiple myeloma program
